This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Napoli, C. Articles by Chiariello, M. Search for Related Content PubMed Articles by Napoli, C. Articles by Chiariello, M. Social Bookmarking                         What's this?

Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia

Division of Cardiology, Department of Medicine, School of Medicine, Federico University of Naples, Naples, Italy

Stefano Lepore

Division of Cardiology, Department of Medicine, School of Medicine, Federico University of Naples, Naples, Italy

Paola Chiariello

Division of Cardiology, Department of Medicine, School of Medicine, Federico University of Naples, Naples, Italy

Mario Condorelli

Division of Cardiology, Department of Medicine, School of Medicine, Federico University of Naples, Naples, Italy

Massimo Chiariello

Division of Cardiology, Department of Medicine, School of Medicine, Federico University of Naples, Naples, Italy

Background: Pravastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It pre vents mevalonate synthesis, reducing endogenous cholesterol production, and reduces cholesterol content in the liver, thus resulting in a down-regulation of low-density lipoprotein receptor production. Gemfibrozil reduces very low-density lipoprotein production and low- density lipoprotein-cholesterol level and increases very low-density lipoprotein catabolism. Therefore, it was suggested that combination therapy with both drugs could effect greater reduction of cholesterol levels as compared to pravastatin alone. The present study was car ried out to evaluate the efficacy and safety of pravastatin as a monotherapy or in combination with gemfibrozil in the treatment of patients with familial type IIb hyperlipoproteinemia or familial combined hyperlipidemia.

Methods and Results: Forty-one patients were included in the study. All patients initially followed 6 weeks of hypolipidemic diet; subsequently they were randomized and received either 20 mg once daily of pravastatin alone (n = 13) or 20 mg of pravastatin together with 600 mg of gemfibrozil twice daily (n = 14). As a control, 14 patients were treated with diet only. The treatment lasted 24 months and clinical evaluation and laboratory tests were done at given time points. Both groups of treated patients showed an early reduction (3 months) of total (about 30% P < .0 vs controls), low-density lipoprotein (about 35%, P < .0 vs con trols) and very low-density lipoprotein cholesterol levels (about 18%, P = NS). In contrast, high-density lipoprotein cholesterol levels increased significantly in patients treated with pravastatin and gemfibrozil (about 20%, P < .05 vs controls). Pravastatin treatment alone reduced the level of serum triglycerides as efficiently as in combination with gemfibrozil. Data showed a sustained normalization of lipid profile until 24 months. However, this effect was achieved in patients that had rather low levels of triglycerides. During the treatment we did not observe any difference in the incidence of possible drug-related side effects. Severe myopathy or rhabdomyolysis was not observed at the doses of the drugs used in our study. Conclusions: Therapy with pravastatin alone and in combination with gemfibrozil resulted in significant and sustained normalization of lipid profile in high-risk patients with familial type lib hyperlipoproteinemia or familial combined hyperlipidemia.

Key Words: pravastatin • gemfibrozil • hypercholesterolemia • familial type IIb hyperlipopro teinemia • familial combined hyperlipidemia.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 2, No. 1, 17-26 (1997)
DOI: 10.1177/107424849700200103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Sharma, M. T. Ansari, A. M. Abou-Setta, K. Soares-Weiser, T. C. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, and D. Moher Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia Ann Intern Med, November 3, 2009; 151(9): 622 - 630. [Abstract] [Full Text] [PDF]

				M. Sharma, M. T. Ansari, A. M. Abou-Setta, K. Soares-Weiser, T. C. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, and D. Moher Systematic Review: Comparative Effectiveness and Harms of Combinations of Lipid-Modifying Agents and High-Dose Statin Monotherapy Ann Intern Med, August 31, 2009; (2009) 0000605-200911030-00144v1. [Abstract] [Full Text]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke, September 1, 2002; 33(9): 2337 - 2341. [Full Text] [PDF]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, C. Lenfant, and Writing Committee Members: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation, August 20, 2002; 106(8): 1024 - 1028. [Full Text] [PDF]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J. Am. Coll. Cardiol., August 7, 2002; 40(3): 567 - 572. [Full Text] [PDF]